Development of small molecule antagonists of HGF/SF and MET signalling to treat metastatic cancer

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1072476

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

The spread of cancer throughout the body, metastasis, is the major cause of death from cancer. The MET receptor plays a crucial role in over 60% of all metastases and several approaches to block its activity are currently in clinical trials. This project will use a new approach to develop small molecule inhibitors that block the MET receptor from interacting with another protein, HGF/SF. Small molecules that block this interaction will be highly effective treatments against metastatic cancers.

Funded Activity Details

Start Date: 01-01-2014

End Date: 01-01-2018

Funding Scheme: Early Career Fellowships

Funding Amount: $353,866.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Biologically Active Molecules

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

biochemistry | biophysics | cancer treatment | drug development | structure-based drug design

Related Links